Menu Search
Equities

Enzymatica AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
EN9:MUN

Enzymatica AB (publ)

Actions
  • Price (EUR)0.177
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+32.58%
  • Beta-0.5561
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.

  • Revenue in SEK (TTM)52.73m
  • Net income in SEK-54.14m
  • Incorporated2007
  • Employees21.00
  • Location
    Enzymatica AB (publ)Ideon Science Park, Scheelevagen 19LUND 223 70SwedenSWE
  • Phone+46 462863100
  • Websitehttps://www.enzymatica.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.